<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BIO CEO</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>BIO CEO 2025: The quest for next-gen obesity meds</title>
      <description>
        <![CDATA[While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several other companies are developing follow-on products that could clean up the tolerability and adherence issues of Wegovy (semaglutide) and Zepbound (tirzepatide).]]>
      </description>
      <guid>http://www.bioworld.com/articles/717261</guid>
      <pubDate>Thu, 13 Feb 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717261-bio-ceo-2025-the-quest-for-next-gen-obesity-meds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Injection-pen-and-measuring-tape.webp?t=1712867123" type="image/jpeg" medium="image" fileSize="142716">
        <media:title type="plain">Injection pens and measuring tape</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2025: Navigating from policy to innovation to patients</title>
      <description>
        <![CDATA[The fast pace in which the Trump administration has rolled out changes to how government and businesses operate – a disruptive effort that appears to be creating a new world order – has caught the attention of biopharma industry leaders who spoke Tuesday at the Biotechnology Innovation Organization’s CEO and Investor Conference in New York.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717106</guid>
      <pubDate>Tue, 11 Feb 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717106-bio-ceo-2025-navigating-from-policy-to-innovation-to-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Woman-holding-display-of-business-regulatory-icons.webp?t=1739313801" type="image/jpeg" medium="image" fileSize="136151">
        <media:title type="plain">Woman holding display of business, regulatory icons</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812</title>
      <description>
        <![CDATA[Cognition Therapeutics Inc. evolved from the work of a neuroscientist and a chemist working in the San Francisco Bay area, seeking out targets to block the effects of Alzheimer’s disease. Since the company’s 2007 inception, it has received close to $200 million in U.S. NIH grant funding. Investors often tell CEO Lisa Ricciardi, who joined the company in 2020: “’That’s because you have a relationship with the FDA.’ Well, no. It’s because it’s competitive” and the company’s research has met the muster. “You have to apply two or three times. … It’s with rigor that these results are generated and that we’re able to get more funding.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/717107</guid>
      <pubDate>Tue, 11 Feb 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717107-bio-ceo-2025-cognition-ceo-debates-policy-while-advancing-ct-1812</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Lisa-Ricciardi-CEO-Cognition-2-11.webp?t=1739313802" type="image/jpeg" medium="image" fileSize="109849">
        <media:title type="plain">Lisa Ricciardi, CEO, Cognition</media:title>
        <media:description type="plain">Lisa Ricciardi, CEO, Cognition Therapeutics</media:description>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2025: A ‘nice upswing’ in VC rounds, but uncertainty looms</title>
      <description>
        <![CDATA[Raising money to advance promising science is a constant struggle, bringing biopharma executive leadership together to learn about investment strategies in the opening session at the Biotechnology Innovation Organization’s CEO and Investor Conference in New York. “We’re bottoms-up investors. If we like the technology, we like the product, we think it’s going to work, we want to find a way to invest,” said Chris Garabedian, chairman and CEO of Xontogeny.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717091</guid>
      <pubDate>Mon, 10 Feb 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717091-bio-ceo-2025-a-nice-upswing-in-vc-rounds-but-uncertainty-looms</link>
    </item>
    <item>
      <title>BIO CEO 2024: AI applications will only become broader</title>
      <description>
        <![CDATA[In a panel discussion with executives at the 2024 BIO CEO conference this week in New York, the consensus emerged that artificial intelligence is here to stay, despite its occasional moments of hype, as its applications continually grow.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706165</guid>
      <pubDate>Thu, 29 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706165-bio-ceo-2024-ai-applications-will-only-become-broader</link>
    </item>
    <item>
      <title>BIO CEO 2024: Policy impact on US election year will linger</title>
      <description>
        <![CDATA[Drug pricing is playing an outsized role in the dynamics of the November U.S. election, creating turbulence for drug companies and for patients that will extend years after the votes are counted. During a Feb. 27 morning session on drug pricing trends during an election year at the BIO CEO & Investor Conference in New York, key opinion leaders spoke about their concerns, including the need to explain drug-pricing rationale to voters and patients in plain terms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706146</guid>
      <pubDate>Tue, 27 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706146-bio-ceo-2024-policy-impact-on-us-election-year-will-linger</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/US-election-illustration.webp?t=1709072440" type="image/jpeg" medium="image" fileSize="179830">
        <media:title type="plain">Hand holding ballot over box, US flag backdrop</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2024: This downturn will end … eventually</title>
      <description>
        <![CDATA[Companies and investors, well aware of the natural up and down fluctuations of the market, keep expecting the current downturn to end. They’ve been expecting it to begin an upturn for the past two years. During a Feb. 26 session on venture capital trends at the BIO CEO & Investor Conference in New York, investors said the tough times might well extend further into 2024 than they would like.]]>
      </description>
      <guid>http://www.bioworld.com/articles/706102</guid>
      <pubDate>Mon, 26 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/706102-bio-ceo-2024-this-downturn-will-end-eventually</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coins-and-charts.webp?t=1614799981" type="image/png" medium="image" fileSize="413156">
        <media:title type="plain">Coins and charts</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2024: Prepping for better times</title>
      <description>
        <![CDATA[Helping executive and investors prepare for better economic times is a strong theme in the upcoming BIO CEO 2024 conference, which runs Feb. 26 and 27 in New York. The annual conference, sponsored by the Biotechnology Innovation Organization, is designed to present a broad, unbiased view of investment opportunities. Panels of experts are set to discuss hot therapeutic areas and the key business issues facing companies and the industry.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705950</guid>
      <pubDate>Wed, 21 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705950-bio-ceo-2024-prepping-for-better-times</link>
    </item>
    <item>
      <title>BIO CEO 2023: Despite high prevalence of pain and addiction, clinical efforts drop, funding flat, BIO report finds</title>
      <description>
        <![CDATA[The Biotechnology Innovation Organization (BIO) found in a new study that 77% of clinical programs focused on pain therapeutics five years ago are no longer active and that financings of companies working in the space are lackluster at best. Meanwhile, oncology companies, targeting an overall smaller market, have raised huge sums of venture capital money, $9.7 billion in 2021 vs. pain and addiction companies’ $228 million.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694124</guid>
      <pubDate>Thu, 09 Feb 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694124-bio-ceo-2023-despite-high-prevalence-of-pain-and-addiction-clinical-efforts-drop-funding-flat-bio-report-finds</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Pills-spilling-out-of-prescription-bottle.webp?t=1635883616" type="image/png" medium="image" fileSize="374430">
        <media:title type="plain">Pills spilling out of prescription bottle</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2023: Mitigating the impacts of the US Inflation Reduction Act</title>
      <description>
        <![CDATA[With the passage of the Inflation Reduction Act in the U.S. in August 2022, biopharma company leaders have re-evaluated pipelines, sought legal advice, and discussed ways to mitigate the potential impacts the legislation will have on pricing therapies and extending their reach to new indications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/694045</guid>
      <pubDate>Tue, 07 Feb 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/694045-bio-ceo-2023-mitigating-the-impacts-of-the-us-inflation-reduction-act</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Drug-prices-pills-cash.webp?t=1588782562" type="image/png" medium="image" fileSize="492078">
        <media:title type="plain">Money and pills</media:title>
      </media:content>
    </item>
    <item>
      <title>BIO CEO 2023: Getting funded in a crowded environment, differentiation is key</title>
      <description>
        <![CDATA[The market downturn has left many biopharma companies searching for new ways to raise funds, with some eyeing the strong venture capital market as a potential resource. But having a disruptive technology and solid data may be the best way to stand out in a sea of companies, say financial executives that participated Feb. 6 in a panel discussion during the first full day of the BIO CEO 2023 conference in New York.]]>
      </description>
      <guid>http://www.bioworld.com/articles/693999</guid>
      <pubDate>Mon, 06 Feb 2023 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693999-bio-ceo-2023-getting-funded-in-a-crowded-environment-differentiation-is-key</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Financing-maze-money-dollar-sign.webp?t=1633989299" type="image/png" medium="image" fileSize="473964">
        <media:title type="plain">Dollar sign at center of maze</media:title>
      </media:content>
    </item>
    <item>
      <title>Slower year ahead, but capital, financing options remain in wake of record 2021 deals</title>
      <description>
        <![CDATA[After two years of record venture capital financing, which peaked during the first quarter of 2021 with a whopping $38.27 billion raised, investments in biopharma have started to drop off, and industry watchers are expecting a slower deal pace ahead. The same is expected for the IPO market, which saw a record 134 companies go public in 2021. Those trends, combined with big pharma’s hefty cash balances, could mean an M&A surge in 2022, though the availability of special purpose acquisition companies could continue to offer private firms an attractive alternative to a buyout.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516136</guid>
      <pubDate>Wed, 16 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516136-slower-year-ahead-but-capital-financing-options-remain-in-wake-of-record-2021-deals</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coins-and-charts.webp?t=1614799981" type="image/png" medium="image" fileSize="413156">
        <media:title type="plain">Coins and charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Multimodal approach, diagnostics key to unlocking precision oncology potential</title>
      <description>
        <![CDATA[Despite big wins in precision oncology – such as last year’s accelerated FDA nod for Amgen Inc.’s Lumakras (sotorasib) in KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer – industry has barely scratched the surface of the field’s potential. Part of the problem is on the scientific front. Only about a third of patients are currently eligible for targeted therapy, since the majority of patients “do not have a known therapeutic vulnerability for which we have a drug match,” Keith Flaherty, director of clinical research at Massachusetts General Hospital, said during a Feb. 14 session at the BIO CEO & Investor Conference. “And that’s a big problem.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/516036</guid>
      <pubDate>Mon, 14 Feb 2022 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516036-multimodal-approach-diagnostics-key-to-unlocking-precision-oncology-potential</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-AI-diagnostic.webp?t=1745257620" type="image/jpeg" medium="image" fileSize="265878">
        <media:title type="plain">Cancer diagnostic illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Machine learning IDs indication, modality, biomarkers as top predictors of clinical success</title>
      <description>
        <![CDATA[Investing in biopharma has never been for the faint of heart. So headline figures unveiled from a clinical development success report during the BIO CEO & Investor Conference Feb. 17, putting the average likelihood of a drug entering phase I development ultimately achieving approval at 7.9% and the average drug development timeline at 10.5 years, appear largely unsurprising. But the addition of machine learning capabilities to the mix helped identify those factors that have the greatest impact on predictive outcome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503724</guid>
      <pubDate>Wed, 17 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503724-machine-learning-ids-indication-modality-biomarkers-as-top-predictors-of-clinical-success</link>
    </item>
    <item>
      <title>Leadership and equity issues explored at BIO CEO &amp; Investor meeting</title>
      <description>
        <![CDATA[In the opening panel of the BIO CEO & Investor digital conference BIO president and CEO Michelle McMurry-Heath explored some of the key issues that are currently impacting the sector with Adena Friedman, president and CEO of Nasdaq, which, this month, marks the 50th anniversary of its launch in 1971.]]>
      </description>
      <guid>http://www.bioworld.com/articles/503718</guid>
      <pubDate>Wed, 17 Feb 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/503718-leadership-and-equity-issues-explored-at-bio-ceo-investor-meeting</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/money-financing-Nasdaq.webp?t=1588794227" type="image/png" medium="image" fileSize="365980">
        <media:title type="plain">Nasdaq building</media:title>
      </media:content>
    </item>
  </channel>
</rss>
